OnCovid: natural history and outcomes of cancer patients during the COVID19 epidemic

The overarching purpose of this retrospective, non-interventional study is to describe the features of COVID-19 infection in cancer patients, investigate its severity in this population and evaluate long-term outcomes.

Imperial PI Dr David Pinato
Trial Sponsor Imperial College London
Study type Observational
Study status Retrospective analysis

Total participants to date

Database of 1520 patients analysed

Since study inception on March 24th, the first interim analysis of a database of 204 cancer patients with Covid-19 has been completed, and the study opened to 8 centres in UK, Spain and Italy, with another 6 joining later.

Two manuscripts have been published to date:

Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients.

Cancer Discovery

A large Imperial-led study has revealed valuable insights into the impact and risk factors for cancer patients with COVID-19.The findings, from almost 900 cancer patients diagnosed with SARS-CoV-2 infection in the UK, Spain, Italy and Germany, highlight a number of key clinical insights. Read More…

Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe


This paper describes outcomes in 204 cancer patients during the initial outbreak of the COVID-19 in Europe from the retrospective, multi-center observational OnCovid study. Read More…


Find out more about the the study, centres and latest news, here.